Novakand Pharma has initiated concrete discussions with Swedish unlisted growth companies regarding a reverse acquisition. In parallel, discussions are underway regarding the divestment of the fractalkine program with the drug candidates rugocrixan and fosrugocrixane. The company has implemented cost-saving measures. If no strategic alternatives are achieved, the board plans to recommend delisting from Nasdaq First North Growth Market and voluntary liquidation. Decisions will be made by the shareholders at a future general meeting.
|
Published October 9, 2025
Novakand Pharma updates on reverse acquisition
Text:
News Desk [email protected]
Notes
VibroSense Dynamics announces delayed deliveries to China
Acarix reports strong growth in Q3 2025
20 percent weight loss for Eli Lilly's amylin agonist
Stable outlook for AstraZeneca
Camurus lowers full-year forecast
Thor Medical signs supply agreement with Telix
FluoGuide strengthens clinical development management
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
How European companies can succeed in the Chinese deal market
FDA concerns delay Xspray Pharma's Dasynoc approval again
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
